Trevi Therapeutics, Inc. (TRVI) Stock Analysis and Metrics

Trevi Therapeutics

NASDAQ: TRVI

$17.54 ▲ +0.36 (+2.10%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.54 Bn

P/E-55.68

Div. Yield0.00

Add ratio to table…

About

Trevi Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis interstitial lung disease other than IPF and refractory cough.

Trevi Therapeutics Inc currently does not have an approved product on the market and therefore does not generate revenue from product sales; the company is in the development stage and relies on external financing to support its research and clinical programs.

Trevi Therapeutics Inc operates in a competitive biopharmaceutical landscape where several companies are pursuing therapies for chronic cough associated with interstitial lung diseases and refractory cough.

Trevi Therapeutics Inc faces competition from other drug developers targeting similar indications. In the IPF related chronic cough space a compound known as BI 1839100 a TRPA1 antagonist was being developed by Boehringer Ingelheim but its development was terminated in 2025. For refractory cough the company expects competition from agents such as gefapixant a P2X3 antagonist that has been withdrawn from FDA review and camlipixant another P2X3 antagonist under development by GSK as well as taplucainium a charged sodium channel blocker being studied by Nocion Therapeutics. Additionally broader classes of agents such as benzonatate opioids corticosteroids proton pump inhibitors and neuromodulators are used off label for cough and represent alternative therapeutic options. Trevi Therapeutics Inc believes its competitive advantage lies in the unique mechanism of Haduvio which acts as a kappa receptor agonist and a mu receptor antagonist reducing cough while limiting abuse potential associated with pure mu agonists. The oral extended release formulation also offers a convenient dosing regimen compared to injectable nalbuphine which has been used for pain for decades. These factors may help differentiate Haduvio in a crowded market.

Trevi Therapeutics Inc intends to treat patients suffering from chronic cough that arises from idiopathic pulmonary fibrosis interstitial lung disease other than IPF and refractory cough. The company plans to market Haduvio to pulmonologists who specialize in interstitial lung disease and to allergists who manage refractory cough patients. Additionally the company may target specialized interstitial lung disease centers of excellence and other respiratory care providers that serve these patient populations.

Investment Thesis

▲ Bull case

Trevi’s lead asset Haduvio is positioned to become the first FDA‑approved therapy for idiopathic pulmonary fibrosis‑related chronic cough, addressing a sizable unmet need among roughly 100,000 U.S. patients who currently lack any approved treatment. The company has secured alignment with the FDA on a clear Phase III pathway, including two pivotal trials designed to capture both durability of effect and a robust safety database, which reduces regulatory risk and accelerates potential NDA submission. Management’s plan to initiate the first Phase III trial in Q2 2026 and a second confirmatory study later in the year demonstrates disciplined execution and confidence in the drug’s effect size, which could enable rapid enrollment given the strong site interest already observed. Successful approval would not only capture a niche market but also create a platform for expanding into related interstitial lung disease indications, leveraging the same pulmonologist network and commercial infrastructure. The underlying science—targeting the P2X3 receptor with a well‑characterized safety profile—offers differentiation from existing antifibrotics and reduces the likelihood of competitive encroachment in the near term. Collectively, these factors suggest the market may be undervaluing the near‑term catalyst of Phase III readouts and the long‑term value of a first‑in‑class cough therapy.
Beyond IPF‑related cough, Trevi’s strategy to pursue a supplemental NDA for non‑IPF interstitial lung disease‑related chronic cough effectively doubles the addressable patient pool, with an estimated 228,000 non‑IPF ILD sufferers of whom 50‑60 % experience uncontrolled cough. The adaptive Phase IIb/Phase III design proposed for this indication allows the company to refine dose and power assumptions based on real‑world data, thereby mitigating development risk while preserving a clear path to approval. Because non‑IPF ILD patients are managed by the same pulmonologists who treat IPF, commercial launch costs can be shared, creating synergies that improve gross margins and accelerate market penetration. The company’s intention to file this supplemental NDA shortly after the IPF approval indicates a disciplined, sequential approach that maximizes capital efficiency and extends the product lifecycle. This expansion could transform Trevi from a single‑indication player into a broader franchise within the fibrotic lung disease space, a trajectory that analysts may not yet be fully pricing into the stock.
Trevi’s financial positioning provides a substantial cushion to execute its ambitious clinical agenda, with approximately $188 million in cash, cash equivalents and marketable securities at year‑end 2025, translating into an expected runway into 2028. This liquidity buffer not only funds the ongoing Phase IIb trials in refractory chronic cough and non‑IPF ILD but also supports the pivotal Phase III program in IPF‑related cough, including the longer 52‑week safety study required by the FDA. The CFO’s emphasis on capital efficiency and the ability to deploy funds strategically across multiple indications reduces the likelihood of near‑term financing dilutive events. Moreover, the company’s track record of using capital efficiently in prior clinical programs suggests that future milestones will be achieved without eroding shareholder value. This strong balance sheet positions Trevi to weather potential setbacks in trial execution while maintaining momentum toward regulatory submissions.
The commercial team has already begun cultivating relationships with key opinion leaders and patient advocacy groups, laying groundwork for rapid uptake once Haduvio receives approval. Early physician feedback highlighted increased awareness of the drug’s efficacy signal from the CORAL trial, suggesting that prescribing intent may be high even before formal launch. The planned Investor and Analyst Day and ATS presentations serve as additional venues to disseminate clinical data, reinforce differentiation, and build momentum among stakeholders. By aligning commercial preparation with clinical progress, Trevi can compress the timeline between approval and meaningful revenue generation, a factor that may be underappreciated by investors focused solely on trial milestones. This proactive commercial readiness could translate into faster adoption and stronger early‑year sales than comparable pipeline peers.
Intellectual property strategy remains active, with management indicating efforts to secure additional IP around dosing regimens, particularly for refractory chronic cough where lower doses may be effective. Successful extension of IP protections could deter generic competition and prolong market exclusivity beyond the typical Hatch‑Waxman period. The company’s ongoing formulation work in parallel with clinical development suggests a proactive approach to lifecycle management, which can sustain long‑term profitability. Investors often overlook the value of incremental IP gains in early‑stage biotechs, yet such protections can significantly enhance the net present value of a product pipeline. Trevi’s focus on securing complementary IP therefore adds a concealed layer of downside protection and upside potential that is not fully reflected in current valuations.

Trevi’s lead asset Haduvio is positioned to become the first FDA‑approved therapy for idiopathic pulmonary fibrosis‑related chronic cough, addressing a sizable unmet need among roughly 100,000 U.S. patients who currently lack any approved treatment. The company has secured alignment with the FDA on a clear Phase III pathway, including two pivotal trials designed to capture both durability of effect and a robust safety database, which reduces regulatory risk and accelerates potential NDA submission. Management’s plan to initiate the first Phase III trial in Q2 2026 and a second confirmatory study later in the year demonstrates disciplined execution and confidence in the drug’s effect size, which could enable rapid enrollment given the strong site interest already observed. Successful approval would not only capture a niche market but also create a platform for expanding into related interstitial lung disease indications, leveraging the same pulmonologist network and commercial infrastructure. The underlying science—targeting the P2X3 receptor with a well‑characterized safety profile—offers differentiation from existing antifibrotics and reduces the likelihood of competitive encroachment in the near term. Collectively, these factors suggest the market may be undervaluing the near‑term catalyst of Phase III readouts and the long‑term value of a first‑in‑class cough therapy.
Beyond IPF‑related cough, Trevi’s strategy to pursue a supplemental NDA for non‑IPF interstitial lung disease‑related chronic cough effectively doubles the addressable patient pool, with an estimated 228,000 non‑IPF ILD sufferers of whom 50‑60 % experience uncontrolled cough. The adaptive Phase IIb/Phase III design proposed for this indication allows the company to refine dose and power assumptions based on real‑world data, thereby mitigating development risk while preserving a clear path to approval. Because non‑IPF ILD patients are managed by the same pulmonologists who treat IPF, commercial launch costs can be shared, creating synergies that improve gross margins and accelerate market penetration. The company’s intention to file this supplemental NDA shortly after the IPF approval indicates a disciplined, sequential approach that maximizes capital efficiency and extends the product lifecycle. This expansion could transform Trevi from a single‑indication player into a broader franchise within the fibrotic lung disease space, a trajectory that analysts may not yet be fully pricing into the stock.
Trevi’s financial positioning provides a substantial cushion to execute its ambitious clinical agenda, with approximately $188 million in cash, cash equivalents and marketable securities at year‑end 2025, translating into an expected runway into 2028. This liquidity buffer not only funds the ongoing Phase IIb trials in refractory chronic cough and non‑IPF ILD but also supports the pivotal Phase III program in IPF‑related cough, including the longer 52‑week safety study required by the FDA. The CFO’s emphasis on capital efficiency and the ability to deploy funds strategically across multiple indications reduces the likelihood of near‑term financing dilutive events. Moreover, the company’s track record of using capital efficiently in prior clinical programs suggests that future milestones will be achieved without eroding shareholder value. This strong balance sheet positions Trevi to weather potential setbacks in trial execution while maintaining momentum toward regulatory submissions.
The commercial team has already begun cultivating relationships with key opinion leaders and patient advocacy groups, laying groundwork for rapid uptake once Haduvio receives approval. Early physician feedback highlighted increased awareness of the drug’s efficacy signal from the CORAL trial, suggesting that prescribing intent may be high even before formal launch. The planned Investor and Analyst Day and ATS presentations serve as additional venues to disseminate clinical data, reinforce differentiation, and build momentum among stakeholders. By aligning commercial preparation with clinical progress, Trevi can compress the timeline between approval and meaningful revenue generation, a factor that may be underappreciated by investors focused solely on trial milestones. This proactive commercial readiness could translate into faster adoption and stronger early‑year sales than comparable pipeline peers.
Intellectual property strategy remains active, with management indicating efforts to secure additional IP around dosing regimens, particularly for refractory chronic cough where lower doses may be effective. Successful extension of IP protections could deter generic competition and prolong market exclusivity beyond the typical Hatch‑Waxman period. The company’s ongoing formulation work in parallel with clinical development suggests a proactive approach to lifecycle management, which can sustain long‑term profitability. Investors often overlook the value of incremental IP gains in early‑stage biotechs, yet such protections can significantly enhance the net present value of a product pipeline. Trevi’s focus on securing complementary IP therefore adds a concealed layer of downside protection and upside potential that is not fully reflected in current valuations.

▼ Bear case

Despite the optimistic FDA alignment, the Phase III program for IPF‑related cough remains subject to significant clinical uncertainty, particularly regarding the magnitude of the treatment effect and the variability of placebo response. The CORAL trial showed only a modest 17 % placebo response, but the larger pivotal studies will be powered over 90 % for the primary endpoint, meaning any shortfall in observed drug‑placebo difference could jeopardize statistical success. Management acknowledged that the placebo effect over a 24‑week duration is still an unknown variable, and they are relying on the trial’s power to “figure it out,” which introduces a degree of unpredictability that could delay or derail approval. If the observed effect size falls short of expectations, the company may need to conduct additional trials or explore dose adjustments, both of which would consume cash and extend timelines. This clinical risk is not fully captured in the current valuation, which assumes a smooth path to NDA submission.
The plan to pursue a supplemental NDA for non‑IPF ILD‑related chronic cough introduces additional regulatory complexity, as this indication is less clearly defined and encompasses a heterogeneous patient population with varied comorbidities. While management emphasized the carryover of learnings from the IPF End‑of‑Phase 2 meeting, the FDA may request further justification for inclusion criteria, endpoint selection, and the adaptive design, potentially leading to delays or requests for additional data. The adaptive approach, although efficient, carries the risk of regulatory skepticism if interim decisions are perceived as opportunistic rather than scientifically rigorous. Any requirement for a stand‑alone Phase III trial beyond the proposed adaptive framework would increase development costs and strain the current cash runway. Investors may be underestimating the hurdles associated with gaining approval for a novel cough indication in a broader ILD population.
Although Trevi reports a cash runway into 2028, the projection assumes that all planned trials will proceed without unexpected expenses, such as costly protocol amendments, additional safety monitoring, or unanticipated manufacturing scale‑up needs. The requirement to maintain a blinded placebo arm for the full 52‑week duration to satisfy the FDA’s safety data request extends the timeline for data readout and increases ongoing trial expenditures. Moreover, should any of the pivotal trials encounter slower‑than‑expected enrollment—despite optimistic site interest—the company could need to invest in site incentives or expand the investigator network, further draining reserves. The CFO’s comment about potentially deploying cash differently hints at internal debates over allocation, suggesting that the runway may be tighter than presented if multiple indications advance concurrently. This financial flexibility risk could become material if clinical milestones slip.
Commercial readiness, while highlighted as a strength, may be overstated given the lack of an approved product and the inherent uncertainty around physician adoption for a novel cough therapy. Early physician awareness reported by the commercial team does not guarantee uptake, particularly when clinicians must navigate reimbursement pathways, formulary restrictions, and potential safety concerns related to the opioid‑derived nalbuphine ER formulation. The company’s reliance on patient advocacy groups and KOL engagements may not translate into broad market penetration if payers remain skeptical about the clinical value proposition versus existing off‑label approaches. Additionally, the potential for off‑label use of generic alternatives in refractory chronic cough could limit the premium pricing power Trevi hopes to achieve. The market may be assuming a smoother commercial launch than the historical trajectory of first‑in‑class cough agents would suggest.
Intellectual property efforts, while noted as ongoing, have not yet yielded concrete extensions beyond the core nalbuphine ER patent, leaving the composition of matter vulnerable to challenges once exclusivity periods expire. The pursuit of additional IP around dosing regimens or formulations remains speculative, and success is contingent on both inventive merit and patent office approval, which can be uncertain and time‑consuming. Should the company fail to secure meaningful supplementary protection, the window for monopoly pricing could be narrower than anticipated, exposing Haduvio to earlier generic entry. This IP vulnerability is a silent risk that could erode long‑term cash flow projections, yet it receives limited emphasis in current communications.

Despite the optimistic FDA alignment, the Phase III program for IPF‑related cough remains subject to significant clinical uncertainty, particularly regarding the magnitude of the treatment effect and the variability of placebo response. The CORAL trial showed only a modest 17 % placebo response, but the larger pivotal studies will be powered over 90 % for the primary endpoint, meaning any shortfall in observed drug‑placebo difference could jeopardize statistical success. Management acknowledged that the placebo effect over a 24‑week duration is still an unknown variable, and they are relying on the trial’s power to “figure it out,” which introduces a degree of unpredictability that could delay or derail approval. If the observed effect size falls short of expectations, the company may need to conduct additional trials or explore dose adjustments, both of which would consume cash and extend timelines. This clinical risk is not fully captured in the current valuation, which assumes a smooth path to NDA submission.
The plan to pursue a supplemental NDA for non‑IPF ILD‑related chronic cough introduces additional regulatory complexity, as this indication is less clearly defined and encompasses a heterogeneous patient population with varied comorbidities. While management emphasized the carryover of learnings from the IPF End‑of‑Phase 2 meeting, the FDA may request further justification for inclusion criteria, endpoint selection, and the adaptive design, potentially leading to delays or requests for additional data. The adaptive approach, although efficient, carries the risk of regulatory skepticism if interim decisions are perceived as opportunistic rather than scientifically rigorous. Any requirement for a stand‑alone Phase III trial beyond the proposed adaptive framework would increase development costs and strain the current cash runway. Investors may be underestimating the hurdles associated with gaining approval for a novel cough indication in a broader ILD population.
Although Trevi reports a cash runway into 2028, the projection assumes that all planned trials will proceed without unexpected expenses, such as costly protocol amendments, additional safety monitoring, or unanticipated manufacturing scale‑up needs. The requirement to maintain a blinded placebo arm for the full 52‑week duration to satisfy the FDA’s safety data request extends the timeline for data readout and increases ongoing trial expenditures. Moreover, should any of the pivotal trials encounter slower‑than‑expected enrollment—despite optimistic site interest—the company could need to invest in site incentives or expand the investigator network, further draining reserves. The CFO’s comment about potentially deploying cash differently hints at internal debates over allocation, suggesting that the runway may be tighter than presented if multiple indications advance concurrently. This financial flexibility risk could become material if clinical milestones slip.
Commercial readiness, while highlighted as a strength, may be overstated given the lack of an approved product and the inherent uncertainty around physician adoption for a novel cough therapy. Early physician awareness reported by the commercial team does not guarantee uptake, particularly when clinicians must navigate reimbursement pathways, formulary restrictions, and potential safety concerns related to the opioid‑derived nalbuphine ER formulation. The company’s reliance on patient advocacy groups and KOL engagements may not translate into broad market penetration if payers remain skeptical about the clinical value proposition versus existing off‑label approaches. Additionally, the potential for off‑label use of generic alternatives in refractory chronic cough could limit the premium pricing power Trevi hopes to achieve. The market may be assuming a smoother commercial launch than the historical trajectory of first‑in‑class cough agents would suggest.
Intellectual property efforts, while noted as ongoing, have not yet yielded concrete extensions beyond the core nalbuphine ER patent, leaving the composition of matter vulnerable to challenges once exclusivity periods expire. The pursuit of additional IP around dosing regimens or formulations remains speculative, and success is contingent on both inventive merit and patent office approval, which can be uncertain and time‑consuming. Should the company fail to secure meaningful supplementary protection, the window for monopoly pricing could be narrower than anticipated, exposing Haduvio to earlier generic entry. This IP vulnerability is a silent risk that could erode long‑term cash flow projections, yet it receives limited emphasis in current communications.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password